Gilead Sciences K.K., the Japan arm of U.S. pharmaceutical company Gilead Sciences, Inc., said Monday that it has filed an application in Japan to allow production and sales of its antiviral drug Remdesivir as a treatment for COVID-19, the disease caused by the new coronavirus.
The Health, Labor and Welfare Ministry aims to approve the drug within a week under the "special approval" system to swiftly screen items at a time of emergency under the Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.
The ministry will hear opinions from a council as early as this week after confirming the effectiveness and safety of the new drug. If there are no problems, the drug will be approved.
Read more from The Japan News at https://japannews.yomiuri.co.jp/
